HAE heads into its August 6 earnings report with the options market sending a clear bullish signal — one that the stock's sharp recent rally has done nothing to contradict.
The most striking positioning data is in options. Call demand has overwhelmed put buying, pushing the put/call ratio to just 0.16, well below its 20-day average of 0.23 and near the lower end of its 52-week range. That's nearly one standard deviation below recent norms — the market is leaning emphatically toward upside rather than protection ahead of the print. The stock has backed that sentiment up with a 15.6% gain over the past month, closing Monday at $86.79, including an 8.6% move in the past week alone. The borrow market reinforces the picture: availability is exceptionally loose at roughly 3,700% — meaning there are far more shares available to lend than are currently borrowed — and cost to borrow sits at just 0.45%. There is no meaningful short pressure here.
Short interest has been drifting lower, which tells a consistent story. At 5.6% of free float, it is not negligible, but it has fallen nearly 10% over the past month and slipped further in the past week. The ORTEX short score has also eased, declining from around 41.7 in late July to 40.4. Shorts have been quietly reducing exposure into the rally rather than adding conviction.
Analysts have been revising upward. Mizuho raised its target to $90 in mid-July, maintaining its Outperform rating — the most recent major move before Thursday's print. BofA upgraded to Buy in late May, and several others have lifted targets since the prior quarter. The consensus mean target of $87.90 now sits roughly at the current price, which compresses the implied upside and sets up the forward guidance as the real swing factor. Bulls point to Haemonetics' MedSurg pivot — particularly plasma and hospital segment growth driven by demand for plasma-derived therapies — as the engine of margin expansion. Bears counter with persistent Blood Center competition and lingering execution questions in Interventional Technologies, where recent commercial stumbles have drawn scrutiny. Citigroup and JPMorgan both hold Neutral ratings, and JPMorgan's $62 target is well below the current price — a notable gap that reflects genuine disagreement on execution risk rather than just valuation style.
The last earnings print, in May, saw HAE gain roughly 4.7% on the day and extend that to an 8.4% five-day move. Thursday's report will test whether the MedSurg transition is delivering the margin profile that justifies a stock now trading roughly 55% above where JPMorgan's analyst is comfortable.
See the live data behind this article on ORTEX.
Open HAE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
